BAY Stock Overview
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €124.76 |
| 52 Week High | €241.00 |
| 52 Week Low | €109.04 |
| Beta | 0.97 |
| 1 Month Change | 2.21% |
| 3 Month Change | -0.98% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -45.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| BAY | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | 7.7% | 2.4% | 0.9% |
| 1Y | n/a | -3.7% | 27.0% |
Return vs Industry: Insufficient data to determine how BAY performed against the Polish Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how BAY performed against the Polish Market.
Price Volatility
| BAY volatility | |
|---|---|
| BAY Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in PL Market | 10.1% |
| 10% least volatile stocks in PL Market | 3.2% |
Stable Share Price: BAY has not had significant price volatility in the past 3 months.
Volatility Over Time: BAY's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1863 | 96,931 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
| BAY fundamental statistics | |
|---|---|
| Market cap | zł119.76b |
| Earnings (TTM) | -zł12.74b |
| Revenue (TTM) | zł206.43b |
0.6x
P/S Ratio-9.4x
P/E RatioIs BAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAY income statement (TTM) | |
|---|---|
| Revenue | €47.64b |
| Cost of Revenue | €19.75b |
| Gross Profit | €27.89b |
| Other Expenses | €30.83b |
| Earnings | -€2.94b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -2.99 |
| Gross Margin | 58.55% |
| Net Profit Margin | -6.17% |
| Debt/Equity Ratio | 132.3% |
How did BAY perform over the long term?
See historical performance and comparison